Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Loxenatide for type 2 diabetes mellitus with nonalcoholic fatty liver disease
ChiCTR2100048768Phase 4Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Aug 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of loxenatide in metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Tongji Hospital. Primary endpoints: Height, Weight and 5 more. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
loxenatide
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2100048768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048768.